Biosimilars Face Barriers In Canada
Confusing, complicated, disconcerting—these are some of the words that advisors participating in The Benefits Alliance Group’s recent roundtable discussion use to describe the market for biologic drugs in Canada today (see page 6 for the names of participants). While no one disputes the value of these life-changing drugs, which use living cells to treat serious …